Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016
Open accessThe DOI matches its Crossref record; 66 of the 69 references it cites were found in a registry or an index; 39 of the 72 sources its claims cite were checked for support.
Abstract
PROBLEM/CONDITION: Candidemia is a bloodstream infection (BSI) caused by yeasts in the genus Candida. Candidemia is one of the most common health care-associated BSIs in the United States, with all-cause in-hospital mortality of up to 30%. PERIOD COVERED: 2012-2016. DESCRIPTION OF SYSTEM: CDC's Emerging Infections Program (EIP), a collaboration among CDC, state health departments, and academic partners that was established in 1995, was used to conduct active, population-based laboratory surveillance for candidemia in 22 counties in four states (Georgia, Maryland, Oregon, and Tennessee) with a combined population of approximately 8 million persons. Laboratories serving the catchment areas were recruited to report candidemia cases to the local EIP program staff. A case was defined as a blood culture that was positive for a Candida species collected from a surveillance area resident during 2012-2016. Isolates were sent to CDC for species confirmation and antifungal susceptibility testing. Any subsequent blood cultures with Candida within 30 days of the initial positive culture in the same patient were considered part of the same case. Trained surveillance officers collected clinical information from the medical chart for all cases, and isolates were sent to CDC for species confirmation and antifungal susceptibility testing. RESULTS: Across all sites and surveillance years (2012-2016), 3,492 cases of candidemia were identified. The crude candidemia incidence averaged across sites and years during 2012-2016 was 8.7 per 100,000 population; important differences in incidence were found by site, age group, sex, and race. The crude annual incidence was the highest in Maryland (14.1 per 100,000 population) and lowest in Oregon (4.0 per 100,000 population). The crude annual incidence of candidemia was highest among adults aged ≥65 years (25.5 per 100,000 population) followed by infants aged <1 year (15.8). The crude annual incidence was higher among males (9.4) than among females (8.0) and was approximately 2 times greater among blacks than among nonblacks (13.7 versus 5.8). Ninety-six percent of cases occurred in patients who were hospitalized at the time of or during the week after having a positive culture. One third of cases occurred in patients who had undergone a surgical procedure in the 90 days before the candidemia diagnosis, 77% occurred in patients who had received systemic antibiotics in the 14 days before the diagnosis, and 73% occurred in patients who had had a central venous catheter (CVC) in place within 2 days before the diagnosis. Ten percent were in patients who had used injection drugs in the past 12 months. The median time from admission to candidemia diagnosis was 5 days (interquartile range [IQR]: 0-16 days). Among 2,662 cases that were treated in adults aged >18 years, 34% were treated with fluconazole alone, 30% with echinocandins alone, and 34% with both. The all-cause, in-hospital case-fatality ratio was 25% for any time after admission; the all-cause in-hospital case-fatality ratio was 8% for <48 hours after a positive culture for Candida species. Candida albicans accounted for 39% of cases, followed by Candida glabrata (28%) and Candida parapsilosis (15%). Overall, 7% of isolates were resistant to fluconazole and 1.6% were resistant to echinocandins, with no clear trends in resistance over the 5-year surveillance period. INTERPRETATION: Approximately nine out of 100,000 persons developed culture-positive candidemia annually in four U.S. sites. The youngest and oldest persons, men, and blacks had the highest incidences of candidemia. Patients with candidemia identified in the surveillance program had many of the typical risk factors for candidemia, including recent surgery, exposure to broad-spectrum antibiotics, and presence of a CVC. However, an unexpectedly high proportion of candidemia cases (10%) occurred in patients with a history of injection drug use (IDU), suggesting that IDU has become a common risk factor for candidemia. Deaths associated with candidemia remain high, with one in four cases resulting in death during hospitalization. PUBLIC HEALTH ACTION: Active surveillance for candidemia yielded important information about the disease incidence and death rate and persons at greatest risk. The surveillance was expanded to nine sites in 2017, which will improve understanding of the geographic variability in candidemia incidence and associated clinical and demographic features. This surveillance will help monitor incidence trends, track emergence of resistance and species distribution, monitor changes in underlying conditions and predisposing factors, assess trends in antifungal treatment and outcomes, and be helpful for those developing prevention efforts. IDU has emerged as an important risk factor for candidemia, and interventions to prevent invasive fungal infections in this population are needed. Surveillance data documenting that approximately two thirds of candidemia cases we
Overview
CoChat Summary
TL;DR
Active population-based surveillance in four U.S. sites during 2012–2016 identified 3,492 candidemia cases, with an average crude incidence of 8.7 per 100,000 population and a 25% all-cause in-hospital case-fatality ratio. Incidence was highest in Maryland, among adults aged ≥65 years and infants, among males, and among blacks; 10% of cases occurred in patients with recent injection drug use.
Key findings
- Across 2012–2016, 3,492 candidemia cases were identified from 3,235 patients; crude incidence averaged 8.7 per 100,000 population, highest in Maryland (14.1) and lowest in Oregon (4.0).
- Crude incidence was highest among adults aged ≥65 years (25.5 per 100,000) and infants aged <1 year (15.8), higher among males (9.4) than females (8.0), and approximately twice as high among blacks as nonblacks (13.7 versus 5.8).
- Common exposures included systemic antibiotics in the 14 days before diagnosis (77%), central venous catheter within 2 days before diagnosis (73%), surgery in the 90 days before diagnosis (33%), and injection drug use in the past 12 months (10%).
- Candida albicans accounted for 39% of cases, followed by C. glabrata (28%) and C. parapsilosis (15%); 7% of isolates were fluconazole-resistant and 1.6% were echinocandin-resistant. The all-cause in-hospital case-fatality ratio was 25% overall and 8% within <48 hours after a positive culture.
Methods
- CDC’s Emerging Infections Program conducted active, population-based laboratory surveillance for culture-confirmed candidemia during 2012–2016 in 22 counties across Georgia, Maryland, Oregon, and Tennessee, with a combined surveillance population of approximately 8.06 million persons.
- A case was a blood culture positive for Candida species from a surveillance-area resident; cultures within 30 days of the initial positive culture in the same patient were considered one episode. Clinical data were abstracted from medical charts, and isolates were sent to CDC for species confirmation and antifungal susceptibility testing.
- Crude incidence rates per 100,000 population were calculated using U.S. Census Bureau denominators; multivariable negative binomial regression assessed adjusted incidence rate ratios by age, sex, race, and site, and univariable negative binomial regression assessed 5-year trends.
Limitations
- The paper states that underlying conditions and predisposing factors were extracted from medical charts, which might underestimate certain conditions such as injection drug use that may not be systematically recorded.
- The paper states that some culture-proven cases might have been missed despite active, audited surveillance, and that blood-culture-based surveillance underestimates invasive candidiasis because blood culture has suboptimal sensitivity, particularly for intra-abdominal candidiasis or infections without blood cultures.
- The paper states that data came from 22 counties in four states representing 2.5% of the U.S. population and are not nationally representative, and that only five time points were assessed, limiting understanding of long-term trends. No additional limitations are evident beyond those stated.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
24 Valid · 4 Not valid · 14 Not checked · 118 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In contrast with the 2009 Infectious Disease Society of America guidelines for the treatment of invasive candidiasis, in which echinocandins were recommended only for neutropenic patients and patients with previous exposure to antifungals (64)”
§ Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 > Discussion
What the sources say
- Disputedcites [64] Pappas PG, Kauffman CA, Andes D, Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503– 35. 10.1086/596757 19191635 PMC7294538 sourceExperimental — accuracy not yet measured
The recommendations for candidemia in nonneutropenic patients (page not supplied) list an echinocandin as initial therapy for most adults, not only for neutropenic patients or those previously exposed to antifungals. They also favor an echinocandin for moderately severe to severe illness, independently of recent azole exposure. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Enhanced infection control practices, including appropriate catheter use to limit catheter-related bloodstream infections (42–44), antibiotic stewardship, and antifungal prophylaxis practices, might be responsible for some of the decreases.”
§ Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 > Discussion
What the sources say
- Partly supportedcites [42] Sanchez GV, Fleming-Dutra KE, Roberts RM, Hicks LA. Core elements of outpatient antibiotic stewardship. MMWR Recomm Rep 2016; 65(No. RR-6). 10.15585/mmwr.rr6506a1 27832047 sourceExperimental — accuracy not yet measured
The Introduction and Background describe antibiotic stewardship as a way to improve prescribing and reduce antibiotic-related harms. They do not connect it to declining candidemia incidence; the paper also does not address catheter use or antifungal prophylaxis as explanations for that decline. (LLM, conf=0.82)
- Partly supportedcites [43] Pappas PG, Kauffman CA, Andes DR, Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62: e1– e50. 10.1093/cid/civ1194 26679628 PMC4725385 sourceExperimental — accuracy not yet measured
Recommendation 13 advises early removal of a central venous catheter when it is the presumed source of candidemia and removal is safe. This supports appropriate catheter management, the part of the sentence to which the citation is attached, but does not establish that catheter practices caused the reported decreases in candidemia incidence. The cited passages have no page numbers. (LLM, conf=0.82)
- Supportedcites [44] Waters TM, Daniels MJ, Bazzoli GJ, Effect of Medicare’s nonpayment for hospital-acquired conditions: lessons for future policy. JAMA Intern Med 2015; 175: 347– 54. 10.1001/jamainternmed.2014.5486 25559166 PMC5508870 sourceExperimental — accuracy not yet measured
The citation is attached to appropriate catheter use to limit catheter-related bloodstream infections, not to antibiotic stewardship or antifungal prophylaxis. The Discussion (page unavailable) describes sterile catheter insertion, earlier catheter removal, and other preventive practices, and reports that care bundles have been associated with fewer central-line–associated bloodstream infections. The paper does not address candidemia specifically. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, availability of both types of testing, especially AFST, is limited in clinical laboratories (62).”
§ Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 > Discussion
What the sources say
- Partly supportedcites [62] Vallabhaneni S, Sapiano M, Weiner LM, Lockhart SR, Magill S. Antifungal susceptibility testing practices at acute care hospitals enrolled in the National Healthcare Safety Network, United States, 2011–2015. Open Forum Infect Dis 2017; 4: ofx175. 10.1093/ofid/ofx175 29026868 PMC5632525 sourceExperimental — accuracy not yet measured
The Results and Discussion report limited access to AFST at a hospital’s own laboratory or an affiliated medical center, and limited reflexive AFST. They also report that 95.5% of surveyed hospitals offered AFST through some route, so the limitation concerns local and reflexive access rather than AFST availability overall. The paper does not establish that species-level identification is limited. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The proportion of candidemia patients with an IDU history is much higher than the estimated <1% of the entire U.S. population with a history of IDU during the previous 12 months (55)”
§ Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 > Discussion
What the sources say
- Partly supportedcites [55] Lansky A, Finlayson T, Johnson C, Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One 2014; 9: e97596. 10.1371/journal.pone.0097596 24840662 PMC4026524 sourceExperimental — accuracy not yet measured
The Results section estimates that 0.30% of the U.S. population aged 13 years or older injected drugs in the past year, supporting the cited figure of less than 1%. The claim says the entire U.S. population, but the paper's estimate excludes children under 13. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The disparity between blacks and nonblacks persisted in all four sites, including in Georgia and Maryland, where 41%–43% of the surveillance catchment area residents were black, and in Oregon and Tennessee, where 4%–6% of catchment area residents were black.”
§ Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 > Results > Demographic Characteristics and Incidence
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
95 more claims
Create a free account to see all 160 claims and to verify the 5 references still open.
- Probably not a substantial claim. 32
- It may state two separate claims as one. 40
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In multiple population studies over the last two decades, C. albicans is almost uniformly susceptible to fluconazole, the echinocandins, and amphotericin B.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“C. albicans remains the most common cause of bloodstream infections due to Candida and other forms of invasive candidiasis in most regions of the world.18,27,62,102,103,107–109”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Echinocandin resistance remains low at 0–2% in most surveys.27,62”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During 2021, the all-cause mortality rate associated with candidemia was higher compared with earlier years (36.1% versus 26.8% in 2017 and 25% during 2012–2016), and cases during 2020–2021 also more frequently involved previous ICU stays and onset in the health care setting.”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — 10 Sites, United States, 2017–2021 (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Differences in candidemia incidence by age, sex, racial and ethnic group, and geographic region were consistent with previous surveillance data (3).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — 10 Sites, United States, 2017–2021 (2025) · cites this paper as [3]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 > Results > Case Classification
“† Culture positive for Candida was obtained <3 days before admission for a patient with a recent health care exposure.”
§ Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 > Methods > Variables Assessed
“as a health care–associated community-onset case when the culture was obtained <3 days after admission for a patient with a recent health care exposure;”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| C. albicans | 636 (40) | 338 (35) | 129 (40) | 204 (42) | 1,307 (39) |”
§ Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 > Results > Species Distribution
Reported 39 · recomputed 37.449857
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 > Results > Antifungal Treatment
“Of the 19% of cases in patients not receiving antifungal treatment”
§ Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 > Results > Previous Candidemia and Previous Antifungal Treatment
“| Systemic antifungal therapy for candidemia episode† | 1,391 (85) | 834 (82) | 288 (83) | 363 (73) | 2,876 (82) |”
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 8×
“Inflammatory bowel disease 20 (1) 14 (1) 3 (1) 1 (0) 38 (1)”
BackgroundInfluentialHidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers.
Hillenkamp, F., Karas, M., Beavis, R. C., & Chait, B. T. (1991) · Analytical Chemistry · doi:10.1021/ac00024a716 · Cited by 1,930 · cited 5×
“White 518 (34) 337 (37) 234 (70) 421 (89) 1,510 (47)”
MethodInfluentialLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 1×
“Central venous catheter in the 2 days before candidemia diagnosis 1,251 (77) 760 (74) 206 (60) 333 (67) 2,550 (73)”
Self-citationPappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636 · cited 5×
“Although neutropenia (53,54), hematologic malignancies (53), and bone marrow transplants (10,13) are well-recognized risk factors for candidemia, only a small proportion (<5%) of cases were in patients with these underlying conditions.”
BackgroundInfluentialMokdad (2018) · doi:10.1001/jama.2018.0158 · Cited by 1,517
Satoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381 · cited 5×
“auris, which was first described in 2009 (21) and has since been reported in approximately 30 countries, including the United States (22).”
BackgroundInfluentialKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 5×
“tropicalis 120 (8) 107 (11) 17 (5) 48 (10) 292 (9)”
BackgroundInfluentialWeiner, L. M., Webb, A. K., Limbago, B., Dudeck, M. A., Patel, J., Kallen, A. J., Edwards, J. R., & Sievert, D. M. (2016) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2016.174 · Cited by 1,313
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298 · cited 1×
“In contrast with the 2009 Infectious Disease Society of America guidelines for the treatment of invasive candidiasis, in which echinocandins were recommended only for neutropenic patients and patients with previous exposure to antifungals (64), the 2016 guidelines recommend echinocandins as the initial therapy for tre…”
ResultChanges in prevalence of health care-associated infections in U.S. hospitals
Magill, S. S., O’Leary, E., Janelle, S. J., Thompson, D. L., Dumyati, G., Nadle, J., Wilson, L. E., Kainer, M. A., Lynfield, R., Greissman, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801550 · Cited by 1,249
Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989.
Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T., Edwards, J. R., Tolson, J., Henderson, T., Martone, W. J., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90349-3 · Cited by 880
Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016.
Seth, P., Scholl, L., Rudd, R. A., & Bacon, S. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6712a1 · Cited by 821
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 3×
“glabrata isolates in the United States (19,20).”
Contribution of major diseases to disparities in mortality.
Wong, M. D., Shapiro, M. F., Boscardin, W. J., & Ettner, S. L. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa012979 · Cited by 774 · cited 3×
“Fluconazole 972 (60) 505 (49) 206 (60) 256 (51) 1,939 (56)”
BackgroundFirst hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768
Murray, C. J. L., Kulkarni, S. C., Michaud, C., Tomijima, N., Bulzacchelli, M. T., Iandiorio, T. J., & Ezzati, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030260 · Cited by 762
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679 · cited 1×
“Although neutropenia (53,54), hematologic malignancies (53), and bone marrow transplants (10,13) are well-recognized risk factors for candidemia, only a small proportion (<5%) of cases were in patients with these underlying conditions.”
BackgroundParczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Self-citationCore elements of outpatient antibiotic stewardship.
Sanchez, G. V., Fleming-Dutra, K. E., Roberts, R. M., & Hicks, L. A. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6506a1 · Cited by 607 · cited 2×
“Intensive care unit admission in the 14 days before or after candidemia diagnosis 953 (59) 640 (63) 139 (40) 211 (42) 1,943 (56)”
BackgroundChanges in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547 · cited 2×
“Black 843 (56) 539 (59) 25 (7) 36 (8) 1,443 (45)”
BackgroundSelf-citationFluconazole prophylaxis against fungal colonization and infection in preterm infants.
Kaufman, D., Boyle, R., Hazen, K. C., Patrie, J. T., Robinson, M., & Donowitz, L. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010494 · Cited by 523 · cited 4×
“Hepatitis C 66 (4) 165 (16) 54 (16) 67 (13) 352 (10)”
BackgroundInfluentialWelsh, R. M., Bentz, M. L., Shams, A., Houston, H., Lyons, A., Rose, L. J., & Litvintseva, A. P. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00921-17 · Cited by 499 · cited 1×
“Systemic antibiotics in the 14 days before candidemia diagnosis 1,268 (78) 855 (84) 235 (68) 340 (68) 2,698 (77)”
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Vivolo-Kantor, A. M., Seth, P., Gladden, R. M., Mattson, C. L., Baldwin, G. T., Kite-Powell, A., & Coletta, M. A. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6709e1 · Cited by 428
Revisiting the source of candidemia: skin or gut?
Nucci, M., & Anaissie, E. (2001) · Clinical Infectious Diseases · doi:10.1086/323759 · Cited by 424
Rees, J. R., Pinner, R. W., Hajjeh, R. A., Brandt, M. E., & Reingold, A. L. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1138 · Cited by 397 · cited 1×
“Socioeconomic factors might be a proxy for race differences and could play a role in candidemia incidence disparities (48,49).”
BackgroundEchinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374 · cited 2×
“parapsilosis exists because of a naturally occurring variation in the protein target for echinocandins (61), no echinocandin resistance was identified among C.”
BackgroundRisk Factors for Hospital-Acquired Candidemia: A Matched Case-Control Study
Wey, S. B. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390100145030 · Cited by 369 · cited 5×
“tropicalis 120 (8) 107 (11) 17 (5) 48 (10) 292 (9)”
BackgroundInfluentialCleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366
Self-citationCleveland, A. A., Harrison, L. H., Farley, M. M., Hollick, R., Stein, B., Chiller, T. M., Lockhart, S. R., & Park, B. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120452 · Cited by 304
Self-citationVallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6544e1 · Cited by 302
Self-citationLockhart, S. R., Iqbal, N., Cleveland, A. A., Farley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R., Park, B. J., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01283-12 · Cited by 299
Self-citationThe global burden of fungal diseases
Vallabhaneni, S., Mody, R. K., Walker, T., & Chiller, T. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.004 · Cited by 292 · cited 8×
“Amphotericin B 95 (6) 54 (5) 15 (4) 9 (2) 173 (5)”
BackgroundInfluentialSelf-citationChow, N. A., Gade, L., Tsay, S. V., Forsberg, K., Greenko, J. A., Southwick, K. L., Barrett, P. M., Kerins, J. L., Lockhart, S. R., Chiller, T. M., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30597-8 · Cited by 289
Self-citationFridkin, S. K., Kaufman, D., Edwards, J. R., Shetty, S., Horan, T., & Hospitals, T. N. N. I. S. S. (2006) · Pediatrics · doi:10.1542/peds.2005-1996 · Cited by 284
Amphotericin B-induced nephrotoxicity: a review.
Fanos, V., & Cataldi, L. (2000) · Journal of Chemotherapy · doi:10.1179/joc.2000.12.6.463 · Cited by 259 · cited 2×
“Health care onset* 1,064 (65) 622 (61) 170 (49) 251 (50) 2,107 (60) Health care associated community onset† 451 (28) 358 (35) 121 (35) 183 (37) 1,113 (32) Community onset§ 112 (7) 42 (4) 54 (16) 64 (13) 272 (8)”
BackgroundRestrepo, A., Salazar, M. E., Cano, L. E., Stover, E. P., Feldman, D., & Stevens, D. A. (1984) · Infection and Immunity · doi:10.1128/iai.46.2.346-353.1984 · Cited by 251 · cited 1×
“For paracoccidioidomycosis, the differences in incidence occur in postpubertal age groups (approximately aged ≥12 years), and laboratory research has shown that estrogen levels might have a role in acquisition of fungal diseases (46,47).”
BackgroundLansky, A., Finlayson, T., Johnson, C., Holtzman, D., Wejnert, C., Mitsch, A., Gust, D., Chen, R., Mizuno, Y., & Crepaz, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097596 · Cited by 235 · cited 4×
“Echinocandins 888 (55) 582 (57) 137 (40) 191 (38) 1,798 (51)”
BackgroundInfluentialCandida parapsilosis Is a Significant Neonatal Pathogen: A Systematic Review and Meta-analysis
Pammi, M., Holland, L., Butler, G., Gacser, A., & Bliss, J. M. (2013) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182863a1c · Cited by 206 · cited 4×
“Death 48 hours after positive Candida culture obtained 118 (7) 87 (9) 28 (8) 56 (11) 289 (8)”
InfluentialDimopoulos, G., Ntziora, F., Rachiotis, G., Armaganidis, A., & Falagas, M. E. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181607262 · Cited by 189 · cited 4×
“Total parenteral nutrition in the 14 days before candidemia diagnosis 506 (31) 182 (18) 58 (17) 87 (17) 833 (24)”
BackgroundInfluentialVallabhaneni, S., Cleveland, A. A., Farley, M. M., Harrison, L. H., Schaffner, W., Beldavs, Z. G., Derado, G., Pham, C. D., Lockhart, S. R., & Smith, R. M. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv163 · Cited by 187 · cited 5×
“However, as reported in a previous publication using EIP surveillance data, resistance tends to be concentrated in a few tertiary care hospitals that care for highacuity patients with malignancies and transplants; three hospitals out of 80 included in the candidemia EIP surveillance accounted for more than half of all…”
MethodInfluentialSelf-citationPfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00248-12 · Cited by 174 · cited 2×
“Isolates were categorized as resistant to each drug using the 2012 CLSI M27-S4 species-specific breakpoints (36).”
MethodSelf-citationSegal, B. H., Almyroudis, N. G., Battiwalla, M., Herbrecht, R., Perfect, J. R., Walsh, T. J., & Wingard, J. R. (2007) · Clinical Infectious Diseases · doi:10.1086/510677 · Cited by 168 · cited 5×
“This might be due to increasing use of antifungal prophylactic regimens among patients with leukemia or lymphoma, patients who received bone marrow transplants, and chemotherapy recipients (15).”
BackgroundInfluentialRisk factors for candidemia in critically ill infants: a matched case-control study.
Feja, K. N., Wu, F., Roberts, K., Loughrey, M., Nesin, M., Larson, E., Della-Latta, P., Haas, J., Cimiotti, J., & Saiman, L. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.02.021 · Cited by 153 · cited 5×
“Previous candidemia 153 (9) 123 (12) 16 (5) 27 (5) 319 (9) Systemic antifungal therapy for candidemia episode† 1,391 (85) 834 (82) 288 (83) 363 (73) 2,876 (82)”
BackgroundInfluentialEffect of Medicare’s Nonpayment for Hospital-Acquired Conditions: Lessons for Future Policy
Waters, T. M., Daniels, M. J., Bazzoli, G. J., Perencevich, E., Dunton, N., Staggs, V. S., Potter, C., Fareed, N., Liu, M., & Shorr, R. I. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5486 · Cited by 147
Jackson, K. A., Bohm, M. K., Brooks, J. T., Asher, A., Nadle, J., Bamberg, W. M., Petit, S., Ray, S. M., Harrison, L. H., Lynfield, R., et al. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6722a2 · Cited by 139
Self-citationEpidemiology of hospitalizations associated with invasive candidiasis, United States, 2002-20121
Strollo, S., Lionakis, M. S., Adjemian, J., Steiner, C. A., & Prevots, D. R. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2301.161198 · Cited by 129
Inhibition by estrogens of conidium-to-yeast conversion in the fungus Paracoccidioides brasiliensis
Salazar, M. E., Restrepo, A., & Stevens, D. A. (1988) · Infection and Immunity · doi:10.1128/iai.56.3.711-713.1988 · Cited by 127 · cited 2×
“White 518 (34) 337 (37) 234 (70) 421 (89) 1,510 (47)”
BackgroundInvasive candidiasis in immunocompromised hospitalized patients.
Sims, C. R., Ostrosky-Zeichner, L., & Rex, J. H. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.05.015 · Cited by 124 · cited 5×
“tropicalis 120 (8) 107 (11) 17 (5) 48 (10) 292 (9)”
BackgroundInfluentialSee, I., Wesson, P., Gualandi, N., Dumyati, G., Harrison, L. H., Lesher, L., Nadle, J., Petit, S., Reisenauer, C., Schaffner, W., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw808 · Cited by 105
Self-citationMultistate Epidemiology of Histoplasmosis, United States, 2011–20141
Armstrong, P. A., Jackson, B. R., Haselow, D., Fields, V., Ireland, M., Austin, C., Signs, K., Fialkowski, V., Patel, R., Ellis, P., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2403.171258 · Cited by 105 · cited 3×
“Unlike other pathogenic fungi, such as Coccidioides and Histoplasma species, which are more prevalent in the environment in specific geographic parts of the United States and hence result in varying incidence geographically (38,39), Candida is believed to be commensal in the human host.”
BackgroundSelf-citationThe national nosocomial infections surveillance system: plans for the 1990s and beyond.
Gaynes, R. P., Culver, D. H., Emori, T. G., Horan, T. C., Banerjee, S. N., Edwards, J. R., Jarvis, W. R., Tolson, J. S., Henderson, T. S., Hughes, J. M., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90355-2 · Cited by 84 · cited 3×
“All-cause in-hospital case-fatality ratio 394 (24) 280 (27) 69 (20) 130 (26) 873 (25)”
BackgroundBenedict, K., Roy, M., Kabbani, S., Anderson, E. J., Farley, M. M., Harb, S., Harrison, L. H., Bonner, L., Wadu, V. L., Marceaux, K., et al. (2018) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piy009 · Cited by 81
Self-citationCoccidioidomycosis Outbreaks, United States and Worldwide, 1940–2015
Freedman, M., Jackson, B. R., McCotter, O., & Benedict, K. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2403.170623 · Cited by 80
Self-citationReemergence of intravenous drug use as risk factor for candidemia, Massachusetts, USA.
Poowanawittayakom, N., Dutta, A., Stock, S., Touray, S., Ellison, R. T., & Levitz, S. M. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2404.171807 · Cited by 58
Notes from the Field: Surveillance for Candida auris — Colombia, September 2016–May 2017
Escandón, P., Cáceres, D. H., Espinosa-Bode, A., Rivera, S., Armstrong, P., Vallabhaneni, S., Berkow, E. L., Lockhart, S. R., Chiller, T., Jackson, B. R., et al. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6715a6 · Cited by 42
Self-citationDecreasing rates of invasive candidiasis in pediatric hospitals across the United States.
Fisher, B. T., Ross, R. K., Localio, A. R., Prasad, P. A., & Zaoutis, T. E. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit679 · Cited by 35 · cited 2×
“All-cause in-hospital case-fatality ratio 394 (24) 280 (27) 69 (20) 130 (26) 873 (25)”
Alp, S., Arikan‐Akdagli, S., Gulmez, D., Ascioglu, S., Uzun, O., & Akova, M. (2015) · Mycoses · doi:10.1111/myc.12349 · Cited by 32
Ramos, R., Caceres, D. H., Perez, M., Garcia, N., Castillo, W., Santiago, E., Borace, J., Lockhart, S. R., Berkow, E. L., Hayer, L., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00371-18 · Cited by 32
Self-citationDeak, E., Etienne, K. A., Lockhart, S. R., Gade, L., Chiller, T., & Balajee, S. A. (2010) · Canadian Journal of Microbiology · doi:10.1139/w10-003 · Cited by 29 · cited 3×
“At CDC’s fungal reference laboratory, Candida species identification from isolates obtained from blood during 2012–2014 was performed using a Luminex assay or DNA sequencing of the D1/D2 subunit of the 28S ribosomal DNA (rDNA) (33).”
MethodSelf-citationVallabhaneni, S., Sapiano, M., Weiner, L. M., Lockhart, S. R., & Magill, S. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx175 · Cited by 14 · cited 1×
“However, availability of both types of testing, especially AFST, is limited in clinical laboratories (62).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—third edition [Internet]. CLSI document no. M27–A3. Vol. 27, No. 9. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. https://clsi.org/media/1461/m27a3_sample.pdf
Cited by
The rapid emergence of antifungal-resistant human-pathogenic fungi
Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 308
“Risk factors for C. auris infection mirror those for infections by other Candida species including recent surgery, immunosuppression, neutropenia, extended health-care exposure and use of antibiotics 55 .”
BackgroundSelf-citationLass-Flörl, C., Kanj, S. S., Govender, N. P., Thompson, G. R., Ostrosky- Zeichner, L., & Govrins, M. A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00503-3 · Cited by 298
Candidemia and Invasive Candidiasis
McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.007 · Cited by 260
Burden of Candidemia in the United States, 2017
Tsay, S. V., Mu, Y., Williams, S., Epson, E., Nadle, J., Bamberg, W. M., Barter, D. M., Johnston, H. L., Farley, M. M., Harb, S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa193 · Cited by 163
Self-citationThe Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) Pandemic
Seagle, E. E., Jackson, B. R., Lockhart, S. R., Georgacopoulos, O., Nunnally, N. S., Roland, J., Barter, D. M., Johnston, H. L., Czaja, C. A., Kayalioglu, H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab562 · Cited by 141
Self-citation
Metadata
- Authors
- Toda, M., Williams, S. R., Berkow, E. L., Farley, M. M., Harrison, L. H., Bonner, L., Marceaux, K. M., Hollick, R., Zhang, A. Y., Schaffner, W., Lockhart, S. R., Jackson, B. R., & Vallabhaneni, S.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Emory University (US)
- Johns Hopkins University (US)
- Oregon Health Authority (US)
- Vanderbilt University (US)
- Corresponding author
- Toda, Mitsuru
- ORCID
- Venue
- MMWR Surveillance Summaries
- Published
- 2019-09-27
- Volume
- 68
- Issue
- 8
- Pages
- 1-15
- ISSN
- 1545-8636 (ISSN-L)
- 1546-0738
- PMC
- PMC6772189
- OpenAlex
- W2976411969
- Cited by
- 198
- References
- 69
- Citations by year
- 2026: 15 · 2025: 34 · 2024: 24 · 2023: 32 · 2022: 36 · 2021: 34 · 2020: 21 · 2019: 2
- FWCI
- 17.82
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- public-domain
- Locations
- MMWR Surveillance Summaries (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- candidemia, candidemia incidence, Emerging Infections Program, active surveillance, antifungal susceptibility, antifungal resistance, geographic variation in incidence, racial disparities, age and sex differences, hospitalized patients, nosocomial infections, Maryland, Oregon, Tennessee, United States
- MeSH terms
- Adolescent, Adult, Aged, Candida, Child, Child, Preschool, Culture Media, Female, Humans, Infant, Male, Middle Aged, Population Surveillance, United States, Age Distribution, Sex Distribution, Racial Groups, Young Adult, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.